Rhythm Pharmaceuticals

Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.

 
 

Developing and commercializing therapies for the treatment of rare genetic disorders of obesity.

Learn More

 

Rare Genetic Disorders of Obesity

Our lead product candidate, setmelanotide, is an investigational, first-in-class MC4R agonist undergoing clinical trials for the treatment of rare genetic disorders of obesity.

LEARN ABOUT OUR PRODUCT PIPELINE ▸

 

FOR PHYSICIANS & PATIENTS

The Genetic Obesity Project is an online resource dedicated to improving the understanding of severe obesity that results from specific genetic disorders.

VISIT WEBSITE ▸

Developing and commercializing therapies for the treatment of rare genetic disorders of obesity.

Learn More ▸

EZ Home Bottom #2

This is Dynamik Widget Area. You can add content to this area by going to Appearance > Widgets in your WordPress Dashboard and adding new widgets to this area.